Rigel Pharmaceuticals

Biotech · Public

Tavalisse (fostamatinib), a SYK inhibitor small-molecule therapeutic

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · rigel.com

Sector
Biotech
Total capital
$750K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$750K
1 award · Health and Human S
Rank in Biotech#206 of 4373
Granted patents
22
18 pending · first 2023
Rank in peer group#5 of 1449

Capital timeline

2023FEDERAL ↑EQUITY ↓Cumulative $750K$750K
2023FEDERAL ↑EQUITY ↓Cumulative $750K$750K

Latest events

  • Federal contractHealth and Human S · Rigel Pharmaceuticals: The Overall Objective Of This Contract Is To Evaluate The Impact Of Fostamatinib Treatment During Hospitalization Resulting From Ards On Long-term Outcomes Including Clinical, Biomarker, Imaging, Qol, Functional And Lung Functi$750K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#5 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 22 granted of 40
Show all 40 patent records
  • JUMPCODE GENOMICSSimilar federal contract value in Biotech · $765K in contracts
  • GenomaticaSimilar federal contract value in Biotech · $761K in contracts
  • ATUX ISKAY GROUP LLCSimilar federal contract value in Biotech · $755K in contracts
  • GRYPHON BIO INCSimilar federal contract value in Biotech · $749K in contracts
  • RenBio, Inc.Similar federal contract value in Biotech · $749K in contracts
  • GEN1E LIFESCIENCES INC.Similar federal contract value in Biotech · $749K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .